Page last updated: 2024-08-23

pravastatin and transforming growth factor beta

pravastatin has been researched along with transforming growth factor beta in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (26.67)	18.2507
2000's	10 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Kanaki, T; Kitahara, M; Miyakoshi, C; Saito, Y; Tamaki, T; Tanaka, S; Toyoda, K	1
Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ	1
Kurata, H; Murakawa, Y; Tajima, N; Utsunomiya, K; Yokota, T	1
Axel, DI; Fenchel, M; Herzog, UU; Karsch, KR; Riessen, R; Rossmann, H	1
Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M	1
El-Sohemy, A	1
Egashira, K; Inoue, S; Kataoka, C; Kitamoto, S; Koyanagi, M; Ni, W; Takeshita, A	1
Fujita, T; Izumo, N; Koida, M; Nakamuta, H	1
Baccante, G; Cuccurullo, F; Di Febbo, C; Di Nisio, M; Porreca, E	1
Bang, BK; Jung, JY; Kim, J; Kim, SB; Kim, YS; Li, C; Lim, SW; Park, JH; Sun, BK; Yang, CW	1
Baccante, G; Cuccurullo, F; Di Marcantonio, MC; Mincione, G; Piccirelli, A; Porreca, E	1
Chen, Y; Kiyomoto, H; Kohno, M; Mizushige, K; Ohmori, K; Sato, C; Shinomiya, K; Takeuchi, H; Yu, Y	1
Chen, TH; Chen, WM; Chou, SH; Ko, YC; Kuo, TK; Lee, OK; Li, HJ; Su, Y	1
Alam, S; Hashiba, Y; Iseki, S; Marukawa, K; Nakagawa, K; Sakulsak, N; Ueki, K; Yamamoto, E	1
Gari, M; Kumar Mariappan, A; Kumar, A; Kumar, D; Kumar, T; Lingaraju, MC; Parida, S; Rana, A; Sharma, M; Singh, TU	1

Reviews

1 review(s) available for pravastatin and transforming growth factor beta

Article	Year
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta	1999

Article

Year

Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.

Kidney international. Supplement, 1999, Volume: 71

Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta

1999

Trials

1 trial(s) available for pravastatin and transforming growth factor beta

Article	Year
Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. Journal of the American College of Cardiology, 2002, Jun-05, Volume: 39, Issue:11 Topics: Anticholesteremic Agents; Cholesterol; Cross-Over Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Pravastatin; Transforming Growth Factor beta; Triglycerides	2002

Article

Year

Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin.

Journal of the American College of Cardiology, 2002, Jun-05, Volume: 39, Issue:11

Topics: Anticholesteremic Agents; Cholesterol; Cross-Over Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Pravastatin; Transforming Growth Factor beta; Triglycerides

2002

Other Studies

13 other study(ies) available for pravastatin and transforming growth factor beta

Article	Year
NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Japanese journal of pharmacology, 1998, Volume: 77, Issue:2 Topics: Animals; Aorta; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell Line; DNA; Eukaryotic Cells; Extracellular Matrix; Fibronectins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Quinolines; Rabbits; Simvastatin; Transforming Growth Factor beta; Tunica Intima; Tunica Media	1998
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Diabetic Nephropathies; Gene Expression; Genes, ras; Glomerular Mesangium; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta	1999
Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic research in cardiology, 1999, Volume: 94, Issue:5 Topics: Cell Division; Cells, Cultured; Collagen; DNA; Extracellular Matrix Proteins; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin; Thrombospondins; Transcription, Genetic; Transforming Growth Factor beta	1999
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochemical and biophysical research communications, 2000, May-19, Volume: 271, Issue:3 Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured	2000
Statin drugs and the risk of fracture. JAMA, 2000, Oct-18, Volume: 284, Issue:15 Topics: Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cholestyramine Resin; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Risk; Transforming Growth Factor beta	2000
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circulation research, 2001, Aug-31, Volume: 89, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Pressure; Chemokine CCL2; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Macrophages; Male; Monocytes; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide Synthase; Nitrites; Nitroarginine; Peptidyl-Dipeptidase A; Pravastatin; Proliferating Cell Nuclear Antigen; Pyridines; Rats; Rats, Inbred WKY; rhoA GTP-Binding Protein; RNA, Messenger; Systole; Transforming Growth Factor beta; Transforming Growth Factor beta1	2001
Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods and findings in experimental and clinical pharmacology, 2001, Volume: 23, Issue:7 Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Calcification, Physiologic; Calcium; Cell Line; Core Binding Factor Alpha 1 Subunit; Core Binding Factors; Fatty Acids, Monounsaturated; Fluvastatin; GTPase-Activating Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Lovastatin; Mevalonic Acid; Mice; Neoplasm Proteins; Osteoblasts; Osteogenesis; Phosphates; Polyisoprenyl Phosphates; Pravastatin; Protein Prenylation; Sesquiterpenes; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Tumor Cells, Cultured	2001
Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. American journal of physiology. Renal physiology, 2004, Volume: 286, Issue:1 Topics: Animals; Anticholesteremic Agents; C-Reactive Protein; Cyclosporine; Fibrosis; Immunosuppressive Agents; Inflammation Mediators; Kidney; Macrophages; Male; Nephritis; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Osteopontin; Pravastatin; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1	2004
Pravastatin up-regulates transforming growth factor-beta1 in THP-1 human macrophages: effect on scavenger receptor class A expression. Biochemical and biophysical research communications, 2004, Feb-13, Volume: 314, Issue:3 Topics: Antibodies; Blotting, Northern; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Macrophages; Membrane Proteins; Mitogen-Activated Protein Kinases; Phosphorylation; Pravastatin; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Scavenger Receptors, Class A; Scavenger Receptors, Class B; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation	2004
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. Journal of the American College of Cardiology, 2004, Aug-18, Volume: 44, Issue:4 Topics: Animals; Blood Glucose; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; DNA Primers; Glucose Tolerance Test; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Insulin; Leptin; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Triglycerides; Tumor Necrosis Factor-alpha; Ventricular Remodeling	2004
Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. Journal of cellular biochemistry, 2004, Nov-15, Volume: 93, Issue:5 Topics: Antineoplastic Agents; Biomarkers; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Cell Proliferation; Cell Shape; Cell Survival; Cisplatin; Doxorubicin; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mesenchymal Stem Cells; Neuroglia; Phenotype; Polyisoprenyl Phosphates; Pravastatin; Transforming Growth Factor beta	2004
Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2009, Volume: 107, Issue:1 Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Regeneration; Collagen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Ki-67 Antigen; Male; Nasal Bone; Pravastatin; Rabbits; Recombinant Proteins; Transforming Growth Factor beta	2009
Pravastatin attenuates isoprenaline induced cardiac fibrosis in a mouse model. Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2023, Volume: 98, Issue:8 Topics: Animals; Body Weight; Collagen; Fibrosis; Isoproterenol; Mice; Pravastatin; Transforming Growth Factor beta	2023